§ Federal grant opportunity · HT942526ALSRPTDA
DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Development Award
Jamie Shortall Grant Officer is accepting applications for DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Development Award. The deadline is September 30, 2026 and the published award range is Award amount not published.
Key facts
- Funder
- Jamie Shortall Grant Officer
- Application deadline
- September 30, 2026
- Award range
- Award amount not published
- Eligibility
- Eligibility criteria are published in the funding opportunity announcement.
- Geography
- United States
- Focus areas
- Research
- Opportunity number
- HT942526ALSRPTDA
Program overview
Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Development Award (TDA) supports research ranging from preclinical validation of therapeutic leads through U.S. Food and Drug Administration (FDA) Investigational New Drug (IND)-enabling studies. The proposed studies are expected to be empirical in nature and product-driven. Applicants with limited amyotrophic lateral sclerosis (ALS) experience are strongly encouraged to include collaborators with substantial experience in the relevant ALS model systems, endpoints and pathophysiology. Applications supported by this award must begin with lead compounds in hand and must already demonstrate proof-of-concept efficacy data in at least one appropriate preclinical model system of ALS, including whole-animal and cellular model systems. Distinctive Features: Mechanism-specific , predictive/cohort-selective, target engagement and pharmacodynamic biomarker development, in parallel to the main therapeutic effort, is a critical component of the FY26 ALSRP Therapeutic Development Award . If appropriate mechanism-specific biomarkers are already available or currently in development, how the existing biomarkers will improve trial design, patient selection, and efficiency or interpretation of the proposed ALS therapeutic approach must be apparent in the application. Development of biomarkers for the purposes of diagnosis, prognosis, or measurement of general disease progression without consideration of the therapeutic development process will not be supported. Therapeutic candidates which have already been granted an IND are not appropriate for this mechanism.
How to apply
- Confirm your organization meets the eligibility criteria above.
- Read the full funding opportunity announcement from Jamie Shortall Grant Officer.
- Draft your narrative against the funder's stated priorities and review criteria.
- Submit before September 30, 2026, allowing time for registration and validation.
Related grant opportunities
- Rural Decentralized Water System Grant Program
- In Vivo High-Resolution Imaging for Inner Ear Visualization (R01 Clinical Trial optional)
- Cooperative Agreement for In Vivo High-Resolution Imaging for Inner Ear Visualization (U01 Clinical Trial Required)
- Advanced Technological Education
- HEAL INITIATIVE: INTERACT Data Coordination and Integration Center (U24 Clinical Trial Not Allowed)
Find every grant your organization qualifies for
Mavenly scores this opportunity against your mission, geography, and funding history — then drafts the proposal with you and tracks the deadline through submission and reporting.